

SB0437/417674/1

BY: Finance Committee

AMENDMENTS TO SENATE BILL 437
(First Reading File Bill)

AMENDMENT NO. 1

On page 1, strike beginning with “Public” in line 2 down through “Committee” in line 3 and substitute “Maryland Health Insurance Coverage Protection Commission – Review of Drug Transparency and Notification Laws and Initiatives”.

On pages 1 and 2, strike beginning with the first comma in line 4 on page 1 down through “terms” in line 8 on page 2 and substitute “the Maryland Health Insurance Coverage Protection Commission to review certain prescription drug transparency and notification laws and initiatives and certain information for a certain purpose; authorizing the Commission to consider certain studies and receive input from certain experts for a certain purpose; making this Act subject to a certain contingency”.

On page 2, in line 8, strike “expensive” and substitute “the Maryland Health Insurance Coverage Protection Commission and the pricing of prescription”.

On pages 2 and 3, strike in their entirety the lines beginning with line 9 on page 2 through line 2 on page 3, inclusive.

AMENDMENT NO. 2

On page 3, in line 4, strike “the Laws of Maryland read as follows”.

On pages 3 through 13, strike in their entirety the lines beginning with line 5 on page 3 through line 15 on page 13, inclusive, and substitute:

“(a) The Maryland Health Insurance Coverage Protection Commission shall review:

(Over)

(1) prescription drug price transparency and notification laws and initiatives adopted and implemented in other states; and

(2) information on prescription drug pricing reported by prescription drug manufacturers and other entities required to report information under prescription drug transparency laws and initiatives adopted and implemented in other states.

(b) (1) The Commission shall review the laws, initiatives, and information under subsection (a) of this section to assess proposals for the adoption and implementation of laws or other initiatives in the State relating to prescription drug price transparency and notification.

(2) The Commission may consider studies and receive input from experts on prescription drug pricing to perform its review under this section.

(c) The Commission shall include any findings and recommendations from its review of the laws, initiatives, and information under subsection (a) of this section in the annual report of the Commission submitted to the Governor and the General Assembly.”.

On page 13, in line 17, strike “October” and substitute “June”; and in the same line, after “2017” insert “, contingent on the taking effect of Chapter __ (S.B. 571/H.B. 909) of the Acts of the General Assembly of 2017, and if Chapter __ (S.B. 571/H.B. 909) does not become effective, this Act shall be null and void without the necessity of further action by the General Assembly”.